Medical Condition

epilepsy

Total Trials

20

Recruiting Now

20

Trial Phases

Phase 3, Phase 4, EARLY_Phase 1

Epilepsy clinical trials increasingly focus on treatment-resistant epilepsy (TRE) — defined as failure of two adequate antiseizure medication (ASM) trials — where one-third of patients remain uncontrolled. Genetic stratification has driven trials in specific epilepsy syndromes (Dravet, Lennox-Gastaut, SCN1A, KCNQ2) where disease-modifying gene therapy approaches are now being tested.

Active trials investigate fenfluramine for treatment-resistant focal epilepsy, KCNQ2/SCN1A antisense oligonucleotides, sodium selenate for progressive myoclonic epilepsy, novel mTOR inhibitors for TSC-related epilepsy, and responsive neurostimulation (RNS). Seizure frequency and seizure-free rates remain primary endpoints, with ESES and status epilepticus trials gaining traction.

Frequently Asked Questions — epilepsy Clinical Trials

How many clinical trials are currently recruiting for epilepsy?

ClinicalMetric currently tracks 20 actively recruiting clinical trials for epilepsy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for epilepsy?

epilepsy research spans Phase 1 (2 trials), Phase 2 (1 trial), Phase 3 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a epilepsy clinical trial?

Eligibility criteria for epilepsy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Baylor College of Medicine 1 trial

yuanli Zhao 1 trial

Hospices Civils de Lyon 1 trial

Charite University, Berlin, Germany 1 trial

Waad Alkathiri 1 trial

epilepsy

Frequently Asked Questions — epilepsy Clinical Trials

Recruiting Clinical Trials

Intracranial Investigation of Neural Circuity Underlying Human Mood

Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy

Neuroimmunology Registry and Biobank

Levetiracetam Three Times Daily in Epilepsy

Prospective Regional Epilepsy Database

Human Intracranial Electrophysiology

Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy

Pharmacogenetics-Based Study on Individualized Use of Sodium Valproate

Clinical Outcomes of Pregnant Individuals With Epilepsy - Prospective Study

Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy

Tumor Related Epilepsy

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom

Localizing Epileptic Networks Using MRI and iEEG

Lemborexant Treatment of Insomnia Linked to Epilepsy

RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.